Protalix BioTherapeutics (PLX) Tops Q1 EPS by 3c, Revenues Beat

Go back to Protalix BioTherapeutics (PLX) Tops Q1 EPS by 3c, Revenues Beat

Protalix BioTherapeutics Reports First Quarter 2021 Financial Results and Business Update

May 14, 2021 6:50 AM EDT

CARMIEL, Israel, May 14, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the first quarter ended March 31, 2021 and provided a business... More